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The 11
th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March
2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups deﬁned by predictive
markers. Any positive level of estrogen receptor (ER) expression is considered sufﬁcient to justify the use of endocrine
adjuvant therapy in almost all patients. Overexpression or ampliﬁcation of HER2 by standard criteria is an indication for
anti-HER2 therapy for all but the very lowest risk invasive tumours. The corollary is that ER and HER2 must be reliably
and accurately measured. Indications for cytotoxic adjuvant therapy were reﬁned, acknowledging the role of risk
factors with the caveat that risk per se is not a target. Proliferation markers, including those identiﬁed in multigene array
analyses, were recognised as important in this regard. The threshold for indication of each systemic treatment
modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making
algorithm.
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introduction
The 11
th St Gallen conference held in March 2009, which was
attended by >4800 participants from 101 countries,
incorporated incremental information but proposed
a radically different treatment selection algorithm for the
management of early breast cancer. The more we know about
the tumour types underlying the heterogeneity of the disease,
the greater the opportunity to reﬁne treatment choice. It was
recognised that clinical trials are very useful for identifying
effective treatments, but fall short of deﬁning the optimal
treatment of individual patients. For example, local control is
crucial to improve survival on average and especially in
patients at low risk, but is overwhelmed by the risk of distant
metastases in patients at high risk. Similarly, while cytotoxic
chemotherapy improves outcome on average among patients
with endocrine-responsive disease receiving endocrine
therapy, subgroups can be deﬁned by conventional pathology
and by multigene analyses in which little or no additional
beneﬁt accrues from chemotherapy. Judgements must be
made in the care of individual patients of whether to use or
withhold each treatment modality. It is the intention of this
report to assist in the rational application of evolving
knowledge in reaching these judgements.
St Gallen 2009: news and progress
New information was presented in the areas of genetics,
tumour biology, experimental therapeutics, surgery,
radiation oncology, and adjuvant systemic therapy. Some of
this new information is summarised in Table 1. In the light
of this information, a Panel of 43 experts from around the
world (see Panel members listed in the appendix) again
considered speciﬁc questions to arrive at recommended
principles for the selection of therapies in early breast cancer.
speciﬁc considerations for treatment
choice
In distilling patient and tumour features to reach patient
treatment decisions, the Panel has adopted a fundamentally
different approach from that used in previous consensus
reports [71, 72]. Clinical decisions in systemic adjuvant therapy
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th International Conference on Primary Therapy of Early Breast Cancer and their implications for
patient care
Field or treatment Status of research/implications for patient care
Epidemiology and changes in breast
cancer incidence
Decrease in breast cancer incidence in some countries is a result of recent changes in the use of hormone
replacement therapy in postmenopausal women [1]. Thus, the increased incidence that might be attributed
to the use of estrogen and progestin preparations (induced carcinogenesis? induced progression of subclinical
breast cancer?) is to be considered at least partly reversible [2].
Genetic predisposition The well-established high-penetrance BRCA1 and BRCA2 genes continue to demonstrate multiple mutations
(roughly 2000 each) which make testing technically difﬁcult. Founder mutations in BRCA in some
geographical areas make the detection of mutations easier.
Genome-wide association studies deﬁne an increased number of genes which carry a smaller increase in risk for
breast cancer, but are relatively common in the population. These genes are of little value in counselling
individuals, though they are of biological interest and can potentially identify women at slightly increased risk
which might justify selective screening policies as public health resources are limited [3].
BRCA1 mutations are associated with triple-negative phenotype, which require clinical evaluation of
novel therapeutic approaches including poly (ADP-ribose) polymerase inhibitors and DNA-damaging
agents [4, 5].
Selective estrogen receptor modulator
(SERM) chemoprevention
Five-year results of lasofoxifene [6] involving >8000 postmenopausal women with osteoporosis were presented.
Two doses of lasofoxifene were studied: the higher dose (0.5 mg daily) proving more effective with
a signiﬁcantly reduced incidence of estrogen receptor-positive breast cancer (the primary study end point),
overall breast cancer, vertebral fracture, nonvertebral fracture, stroke, and major coronary heart disease [7].
These latter features suggest an improved therapeutic ratio compared with tamoxifen prevention. In
particular, there was no increase in endometrial cancer, though there was an increased incidence of venous
thromboembolism, similar to that seen with tamoxifen.
Whole-genome studies A cistrome is a concept incorporating the complete set of interacting related factors across the entire genome.
Advancing technology allowing us to take a more comprehensive overview of events, both genetic and
epigenetic, which inﬂuence particular pathways, such as those involved in steroid receptors. Within the
steroid receptor cistrome, these studies have identiﬁed FOXA1 as an important component [8, 9].
In experimental models, tamoxifen effectiveness requires HER2 suppression which is in turn regulated by the
balance between PAX2 and AIB-1 [10].
Stem cells Further support for the stem-cell hypothesis in breast cancer arises in preclinical studies in which
a subpopulation of cells identiﬁed by aldeﬂuor are uniquely capable of transplanting tumours in animal
models and appear to have the characteristics of self-renewing stem cells [11]. Detection of such cells in
clinical tissue microarrays identiﬁes patients with a relatively poor prognosis [12].
microRNAs MicroRNAs, particularly miR-335 and miR-206, affect metastases by blocking cell migration while
miR-126 blocks cell proliferation. These microRNAs may be lost in highly metastatic cancers and this is
associated with an oligogenic signature indicative of poor prognosis. The predictive potential is being
investigated. Reintroduction of speciﬁc microRNAs has proved to be effective in suppressing metastases in
animal models [13].
Networks in cellular systems Evolution of cell survival mechanisms has required redundant network interactions rather than simple linear
systems. This poses a more complex problem when attacking a cancer cell. Success is more likely to occur if
two or more perturbations can be introduced, preferably at crucial early parts of the network [14]. An
example is the epidermal growth factor receptor (EGFR) family, including HER2.
Circulating tumour cells Circulating tumour cells have been increasingly studied as poor prognosis markers (though they are not yet
ready for routine use). New technology allows the evaluation of phenotypic markers in individual circulating
tumour cells and has demonstrated that these may differ from the gross characteristics of the parent tumour
[15]. Thus, for example, HER2 overexpression in circulating tumour cells might justify targeted therapy even
in the absence of conventional HER2 positivity of the primary tumour. This strategy is undergoing clinical
investigation [16].
Current studies are examining the possibility that some circulating tumour cells may represent breast cancer
stem cells.
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Angiogenesis The beneﬁts of current antiangiogenic treatment in metastatic disease are transitory. Drugs that target
angiogenesis might, in the long run, induce angiogenesis as a rebound phenomenon and have been demonstrated
in preclinical studies to induce tumour progression and metastases [17–19]. A possible mechanism for this
tumour progression may be the release of increasing numbers of circulating endothelial cells following some types
of chemotherapy. Importantly, this effect is not seen with metronomic chemotherapy [20].
Long-term treatment with antiangiogenic drugs together with metronomic chemotherapy was associated with
dramatic and profound reduction of vascular endothelial growth factor (VEGF) and substantial clinical
response in metastatic breast cancer [21]. The type of cancer vascularisation and the extent of VEGF targeting
might be a crucial strategic issue in the treatment of malignancies [22].
Antiangiogenic treatments are under investigation in the adjuvant setting (but are not recommended for routine
use outside clinical trials).
New opportunities for endocrine therapy The mechanism of estrogen effect in cells resistant to estrogen deprivation is apoptosis, which is mediated by
increased calcium inﬂux [23]. Apoptosis is increased by G protein-coupled receptor 30 (GPR30). Which in
turn can be induced by its agonist known as G-1 [24].
Antiangiogenic agents enhance the tamoxifen effect [25].
Cells which are resistant to this estrogen effect have high glutathione, and depletion of glutathione using
buthionine sulphoximine (BSO) will restore full estrogen sensitivity [26].
Resistance to treatment by crosstalk Further studies of the crosstalk between estrogen receptor and HER2 pathways show that each can act as
resistance mechanism for the other. This logically led to studies combining antiestrogenic therapy with agents
targeting receptors of the EGFR family. Examples included the combination of geﬁtinib with either tamoxifen
or anastrozole and the combination of lapatinib with letrozole [27, 28].
Pharmacogenetics The majority but not all studies have associated abnormalities of CYP2D6 on genetic grounds or as a result of
certain antidepressant drugs with poorer outcome among patients treated with tamoxifen [29]. It has been
indicated that increased tamoxifen dosage may overcome less effective metabolic conversion to endoxifen in
some of these patients [30].
Novel imaging Functional imaging using targets of the hormone receptor [31] and HER2 is under development [32].
Multigene assays Multigene assays are widely proposed to add to the prognostic information available from classical
pathological markers and in some circumstances have been shown to identify groups which do or do not
beneﬁt from the addition of chemotherapy to endocrine adjuvant therapy. Surveys of clinical practice
indicate that the information obtained from genetic assays lead to change in treatment decisions in 30%
of cases, mainly to avoid chemotherapy [33]. Trials to further validate this application are currently
underway [34, 35]. No data are available regarding the applicability of these assays for patients with
estrogen receptor-negative disease.
Studies comparing the various genetic proﬁles indicate commonality in sampling groups of genes representing
activation of the steroid hormone receptor pathway, the epidermal growth factor system, and markers of
proliferation. While the former may be useful for speciﬁc treatment selection, the dominant prognostic
information seems to reside within the proliferative marker set [36, 37].
Integrating molecular and other
pathological features
Clinical, pathological, and molecular data may be integrated in more robust prognostic and predictive models.
The best pathology and the most accurate assessment of established markers are key features for a choice of
useful treatment, with appropriate integration of molecular assays [37] which add power to the model [38].
Surgery Results of sentinel node biopsy after neoadjuvant chemotherapy are reliable as described in a meta-analysis [39]
and supported by experience at a single institution [40].
The deﬁnition of adequate surgical margins remains controversial with a majority of North American radiation
oncologists willing to accept a margin as negative if the tumour does not extend to the inked specimen
surface, while surgeons and European radiation oncologists prefer a clearance of 2–5 mm in addition to this
[41]. Invasive tumour found at the inked margin is associated with increased ipsilateral breast tumour
recurrence [42].
Evidence was presented that a more generous margin was required in ductal carcinoma in situ (DCIS), perhaps
reﬂecting the propensity of this disease to discontinuous spread [43]. Lobular carcinoma in situ (LCIS) at the
margin is not regarded as an indication for reexcision [44].
Studies to investigate the necessity of axillary dissection for patients whose sentinel node biopsy contains only
micrometastatic disease (<2 mm) are underway. Meanwhile, experience from a single institution suggests that
the rate of axillary recurrence remains <2% at a median follow-up of 39 months [45].
The use of contralateral prophylactic mastectomy is clearly increasing in several series [46] though the rationale
remains unclear, and evidence that this procedure improves survival is lacking [47].
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Radiation therapy Partial breast irradiation is being studied in several clinical trials but remains experimental. One application
might be the treatment of patients who have already received radiation to part of the breast in the course of
treatment for a previous lymphoma [48].
Recent studies of postmastectomy radiation therapy have attempted to dissect the average survival ratio of one
death prevented for every four local recurrences avoided [49]. In patients at very high risk of relapse, distant
metastases predominate and local control is a less critical determinant of survival. Conversely, in low-risk
cohorts, the ratio may be more favourable and has been reported to approach one death prevented for each
local recurrence avoided [50].
Accelerated partial breast irradiation is being investigated in ongoing trials, but a consensus statement from the
American Society for Therapeutic Radiology and Oncology [51] provides guidance on patients who might be
considered suitable for this technique outside of a study.
Endocrine therapies Either tamoxifen or tamoxifen plus ovarian function suppression, both for the duration of 5 years, is acceptable
standards for premenopausal women with endocrine-responsive disease [52, 53].
Recent results from trials continue to support the beneﬁt of aromatase inhibitors in postmenopausal women
with receptor-positive breast cancer [54, 55], though others have questioned the extent of beneﬁt [56]. Beneﬁt
may be particularly marked for women at higher risk of relapse. For the women at very low risk of recurrence,
there appears to be little beneﬁt from the use of aromatase inhibitors as compared with tamoxifen during the
ﬁrst 5 years [57]. For such patients, it may be wise to choose the best tolerated agent that maximises
adherence and minimises impact on quality of life and health status. The duration of aromatase inhibitor
therapy, supported by trial results, is 2–5 years [57].
HER2-targeted therapy There is some evidence that HER2 positivity carries an adverse prognostic signiﬁcance even in patients with
tumours <1 cm [58], but the relationship to steroid hormone receptor status and adjuvant endocrine or
cytotoxic therapies remains unclear in this group [59, 60].
Chemotherapy There is a lack of speciﬁc predictive markers for response to individual chemotherapeutic agents. Many different
regimens are used and no clear indications for a particular regimen exist. Low estrogen receptor, HER2
overexpression, and increased proliferation predict response to chemotherapy in general, rather than being
agent speciﬁc [61].
Neoadjuvant systemic therapy Preoperative cytotoxic therapy is less effective for tumours with higher levels of estrogen receptor expression [62].
Treatment of triple-negative disease Triple-negative breast cancer is associated with an improved pathological complete response rate with
neoadjuvant chemotherapy [63], but despite this there is an inferior overall survival in comparison to other
breast cancer types [64]. New approaches undergoing clinical trial evaluation for treatment of triple-negative
disease include new agents such as ixabepilone [65] and DNA-damaging agents such as platinum compounds,
anthracyclines, and poly (ADP-ribose) polymerase (PARP) inhibitors [66].
Novel systemic treatments Early clinical investigations are underway to evaluate several promising compounds including new anti-HER2
therapies, HSP-90 inhibitors, mTor inhibitors, anti-IGF1R mAbs, PI3K inhibitors, and antiangiogenesis drugs [67].
Follow-up after treatment
for breast cancer
All the randomized trials on follow-up were conducted before availability of targeted therapies and molecular
markers. A revisiting of early diagnosis of metastases to permit earlier application of targeted therapies is
warranted. Intensive follow-up does not have clinical relevance. Beyond the randomized trials, new
technologies including positron emission tomography scans and the detection of circulating tumour cells
require further evaluation [68].
Speciﬁc news from trials BIG 1-98: Neither the conventional sequence of tamoxifen followed by letrozole nor the reverse sequence of
letrozole followed by tamoxifen proved superior to 5 years of letrozole monotherapy. Early relapses were more
frequent among patients commencing treatment with tamoxifen, particularly in those at higher risk for such
events. Despite substantial crossover among patients assigned tamoxifen monotherapy, the updated
comparison suggested that letrozole monotherapy produced superior survival, though this did not attain
conventional signiﬁcance in the intent-to-treat analysis (P = 0.08) [55].
FinHER update: Updated results of the HER2-positive component in the FinHER study conﬁrmed the beneﬁt
of a 9-week duration treatment with trastuzumab especially if given with docetaxel (at reduced dose).
Exploratory analyses suggested that the trastuzumab beneﬁt was particularly seen among patients receiving
docetaxel rather than vinorelbine during trastuzumab therapy. A prospective study is comparing this short
regimen with a conventional 1-year trastuzumab regimen (SOLD trial) [69].
HERA: Updated analyses to 4-years median follow-up conﬁrmed the value of one year of trastuzumab in
improving disease-free survival, but the overall survival analysis on an intent-to-treat basis has been
complicated by substantial crossover to late use of trastuzumab in the control arm after publication in 2005 of
initial study results. The 2-year treatment group remains blinded [70].
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what justiﬁes the use of endocrine therapy, (ii) what justiﬁes
the use of anti-HER2 therapy, and (iii) what justiﬁes the use of
chemotherapy. Because these decisions are based on quite
separate criteria, the previous attempt to produce a single-risk
categorization and a separate therapy recommendation are no
longer considered appropriate. The new algorithm is
summarised in Table 2. As before, the Panel recognised that
adherence to therapeutic guidelines is affected by affordability
of certain genetic and imaging tests and the costs of some
systemic therapies in various geographic settings.
endocrine therapy
The Panel recommends the inclusion of adjuvant endocrine
therapy in almost all patients whose tumours show evidence
of endocrine responsiveness, now deﬁned as the presence of
any detectable estrogen receptor (ER). It questioned the
validity of reports of positive progesterone receptor (PgR) in
the absence of ER and suggested that such cases be submitted
for further pathological review. Whereas previous categories
of highly endocrine responsive and incompletely endocrine
responsive are not relevant to the decision to use or withhold
endocrine therapy, such consideration remains important for
the selection of patients with ER-positive disease to receive
chemotherapy.
anti-HER2 therapy
Anti-HER2 therapy is indicated in patients with HER2-
positive disease as deﬁned by the American Society of Clinical
Oncology and the College of American Pathologists (ASCO/
CAP) guidelines [74]. The Panel noted that the existing trials
used a slightly less restrictive deﬁnition of HER2 positivity
and acknowledged that patients satisfying the inclusion
criteria used in the trials might also be considered for anti-
HER2 treatment.
chemotherapy
The threshold for use of cytotoxic chemotherapy is the most
difﬁcult to deﬁne. Patients receiving anti-HER2 therapy
conventionally also receive chemotherapy either preceding or
concurrent with the anti-HER2 treatment. Although considered
logical by some of the Panel members, the use of adjuvant anti-
HER2 therapy without chemotherapy remains unsupported by
evidence. Chemotherapy is the mainstay of adjuvant treatment
of patients with triple-negative disease who are at sufﬁcient risk
of relapse to justify its utilisation. Some rare histological types
of breast cancer that fall into the category of triple negative and
are diagnosed neither with axillary node involvement nor with
other signs of increased metastatic potential do not require
adjuvant treatment (e.g. medullary, apocrine, and adenoid
cystic breast cancers). Patients with small primary tumours
(pT1a pN0 and ER negative) might be spared adjuvant systemic
therapy.
The threshold for recommending chemotherapy for patients
with ER-positive, HER2-negative disease is particularly difﬁcult
to deﬁne. These patients include a spectrum from those at low
risk [75, 76] for whom there is little evidence supporting the
addition of chemotherapy to endocrine therapy and to those
with high risk disease and limited ER expression where
chemotherapy appears clearly justiﬁed. Table 3 summarises the
Table 2. Thresholds
a for treatment modalities
Treatment modality Indication Comments
Endocrine therapy Any ER staining
b ER negative and PgR positive are probably
artefactual [73]
Anti-HER2 therapy ASCO/CAP HER2 positive [>30% intense
and complete staining (IHC) or FISH
>2.2+]
b
May use clinical trial deﬁnitions
Chemotherapy
In HER2-positive disease (with anti-HER2
therapy)
Trial evidence for trastuzumab is limited to
use with or following chemotherapy
b
Combined endocrine therapy + anti-HER2
therapy without chemotherapy in
strongly ER-positive, HER2-positive is
logical but unproven
In triple-negative disease Most patients
b,c No proven alternative; most at elevated risk
In ER-positive, HER2-negative disease
(with endocrine therapy)
Variable according to risk
b See Table 3
aMost factors are continuous but a binary decision needs to be made at some level.
bPatients with tumours of <1 cm in size without axillary nodal involvement and without other features indicating increased metastatic potential (e.g. vascular
invasion) might not need adjuvant systemic therapy. If the tumour is, however, endocrine responsive, endocrine therapy should be considered.
cMedullary carcinoma, apocrine carcinoma, and adenoid cystic carcinoma do not require chemotherapy due to low risk despite being triple negative
(provided that, as is usually the case, they have no axillary node involvement and no other signs of increased metastatic risk).
ER, estrogen receptor; PgR, progesterone receptor; ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; IHC,
immunohistochemistry.
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that might justify endocrine therapy alone, and those which are
not useful for making this decision. Features indicating
increased risk of recurrence and thus indirectly supporting the
value of adding chemotherapy to endocrine therapy in such
patients include lower expression of steroid hormone receptors,
grade 3 tumours, high proliferation as measured by
conventional or multigene assays, and the risk factors of four or
more axillary lymph nodes involved, extensive peritumoral
vascular invasion, and tumour size >5 cm. Emerging data
presented but not published indicate that the overall scores
from multigene assays may identify patients in these high-risk
categories who do not gain beneﬁt from the addition of
chemotherapy to endocrine therapy. This represents an
important area of research that will likely be clariﬁed over the
next several years. Patients with high expression of ERs and
PgRs (e.g. >50%), grade 1 tumours, low proliferation, negative
axillary lymph nodes, no peritumoral vascular invasion, and
tumour size £2 cm may be considered for endocrine therapy
alone. We note that some features individually provide little
guidance in reaching a decision to use chemotherapy. In
particular, histological grade 2, intermediate scores on
multigene assays, tumour size between 2 and 5 cm, and low
numbers of involved lymph nodes (one to three) do not
provide deﬁnitive indications to either give or withhold
chemotherapy. However, if all these intermediate criteria are
present, it usually tips the balance towards the use of
chemotherapy. The Panel considered the available multigene
assays in this context and concluded that a validated assay
should be taken into account as an adjunct to high-quality
pathology phenotyping if doubt about the indication for
chemotherapy persists after consideration of other factors.
Considerations of availability and cost determine the current
usefulness of multigene assays. The Panel noted that patients
with pT1a pN0 and ER-positive disease should be offered
endocrine therapy alone even if features which usually indicate
chemotherapy are present.
endocrine responsiveness
Based on the philosophy of deﬁning categories according to
their implications for treatment selection, the previous
three categories of endocrine responsiveness have been
simpliﬁed so that endocrine therapy is considered indicated
if any ER staining is present in the tumour. The majority of
Panellists were in favour of indicating the percentage of
stained cells on pathology reports rather than merely using
scores. Staining for hormone receptors of ‡50% of tumour
cells was viewed as indicating highly endocrine-responsive
tumours.
HER2 positivity
Two technologies are recognised for the determination of
HER2 positivity. These have recently been addressed by a joint
working party of the ASCO/CAP [74]. Either
immunohistochemical analysis showing uniform, intense
membrane staining of >30% of the tumour cells or,
alternatively, determination of gene ampliﬁcation by
ﬂuorescence in situ hybridisation (FISH) (ratio of HER2 gene
Table 3. Chemoendocrine therapy in patients with ER-positive, HER2-negative disease
Relative indications for
chemoendocrine therapy
Factors not useful for decision Relative indications for endocrine
therapy alone
Clinicopathological features
ER and PgR Lower ER and PgR level Higher ER and PgR level
Histological grade Grade 3 Grade 2 Grade 1
Proliferation High
a Intermediate
a Low
a
Nodes Node positive (four or more
involved nodes)
Node positive (one to three
involved nodes)
Node negative
PVI Presence of extensive PVI Absence of extensive PVI
pT size >5 cm 2.1–5 cm £2c m
Patient preference Use all available treatments Avoid chemotherapy-related side-
effects
Multigene assays
Gene signature
b High score Intermediate score Low score
aConventional measures of proliferation include assessment of Ki67-labelling index (e.g. low, £15%; intermediate, 16%–30%; high, >30%) [77] and
pathological description of the frequency of mitoses. The reliability of these measures will vary in different geographic settings. First-generation genetic
signatures contain genes sampling the ER, HER2, and proliferative pathways [78, 79]. Meta-analysis indicates that much of the prognostic information in
these signatures resides in their sampling of proliferative genes [80], but their respective total scores may be the only form in which information is provided at
present and could be used in this component of assessment of relative indications for chemotherapy.
bThe Panel agreed that validated multigene tests, if readily available, could assist in deciding whether to add chemotherapy in cases where its use was
uncertain after consideration of conventional markers.
ER, estrogen receptor; PgR, progesterone receptor; pT, pathological tumour size (i.e. size of the invasive component); PVI, peritumoral vascular invasion.
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situ hybridisation (CISH) (more than six HER2 signals per
nucleus) is sufﬁcient to deﬁne HER2 positivity. Although the
deﬁnitions used in the pivotal trials of trastuzumab were less
restrictive [81–84], a substantial minority of the Panellists
preferred to use 30% intense and complete staining as
a threshold for recommendation of anti-HER2 therapy.
pathological evaluation of
characteristics of the disease
In addition to reporting the presence and type of tumour, the
Panel considered various additional pathological parameters.
Markers of proliferation, and speciﬁcally Ki-67-labelling index,
were considered important for the determination of prognosis
and, importantly, to indicate the potential value of the addition
of chemotherapy to patients with receptor-positive disease.
Ki-67 speciﬁcally was not accepted as the basis for choosing
aromatase inhibitors rather than tamoxifen in postmenopausal
patients with receptor-positive disease [85] as further validation
of ﬁndings in this regard was felt to be necessary [86].
Reporting of ER generated considerable discussion. The Panel
strongly endorsed the reporting of percentage of stained cells
but was evenly divided on whether other scoring methods
should also be reported. PgR was considered valuable for
prognosis, but less important for predicting response to
treatment (e.g. tamoxifen).
The majority of the Panel considered that high grade was
a sufﬁcient indication for chemotherapy and that genomic grade
could be considered as an adjunct to histological grade if readily
available. Gene expression signatures are likely to indicate
a prognostically relevant dichotomy (low grade versus high
grade), though the implications of this observation for therapy
require further study [87, 88]. uPA/PAI-1 was not accepted by
a majority of the Panel as a useful prognostic factor.
In an important change from the previous St Gallen conference
and after a long debate, the Panel supported the use of a validated
multigene-proﬁling assay, if readily available, as an adjunct to
high-quality phenotyping of breast cancer in cases in which the
indication for adjuvant chemotherapy remained uncertain.
local and regional treatments
The aspects considered by the Panel included surgical margins,
indications for sentinel node biopsy, and the role of
prophylactic mastectomy. Re-excision was considered
mandatory if invasive cancer or DCIS is present at the inked
surgical margin, but is not required for lobular carcinoma in
situ (LCIS). The Panel was divided about the need for surgical
margins greater than ‘‘not on ink’’ in DCIS, although no
detailed speciﬁc recommendation was given beside avoiding the
need to insist on a large (e.g. 1 cm) free margin. The use of
surgical procedures developed to allow a wide excision with
satisfactory results (oncoplastic surgery) was also endorsed. The
Panel considered that sentinel node biopsy is the standard of
care for patients with a clinically negative axilla and that axillary
node dissection could be avoided in all patients with a negative
sentinel node and in selected patients with micrometastatic
disease or isolated tumour cells in the sentinel node. A trend to
increasing use of prophylactic contralateral mastectomy was
reported, though it was acknowledged that this procedure was
not associated with any proven survival advantage.
Radiation therapy after local excision of DCIS was
considered to be standard by the Panel members, though most
members considered that it could be avoided in elderly patients
and those with low-grade DCIS and clearly negative margins.
For patients with invasive cancer, postmastectomy radiation
therapy was indicated for those with four or more involved
axillary lymph nodes, but indications for its use in patients with
one to three nodes were considered more restricted and
particularly applicable for young patients and those with other
poor prognostic features. The majority of the Panel considered
that accelerated whole-breast radiation after conservative
surgery was an acceptable option for patients aged ‡60 with
cancers with favourable patterns, but that partial breast
radiation should still be considered experimental. The Panel
considered that endocrine therapy without radiation might be
considered in elderly patients with small tumours, clinically
node-negative and -positive ERs.
adjuvant systemic therapies
The Panel considered targeted therapies against the steroid
hormone receptors and overexpressed HER2 as of prime
importance. In patients whose tumours lack these targets or in
those at higher risk despite the presence of steroid hormone
receptors, the use of chemotherapy requires consideration as set
out in Tables 2 and 3.
endocrine therapy for premenopausal patients
The Panel accepted either tamoxifen or tamoxifen plus ovarian
function suppression as standard endocrine therapies in this
group. Ovarian function suppression alone or ovarian ablation
was considered a possibility only in extraordinary
circumstances. Aromatase inhibitors alone are contraindicated
in premenopausal patients. In case tamoxifen is
contraindicated, aromatase inhibitors may be administered to
premenopausal women together with ovarian function
suppression. Veriﬁcation of ovarian function suppression to
postmenopausal levels is important also in patients under the
age of 60 who are receiving aromatase inhibitors.
Pharmacogenetic determination of tamoxifen metabolism
status as inﬂuenced by CYP2D6 was not considered ready for
routine application in selecting patients for tamoxifen therapy
by the majority of the Panellists.
endocrine therapy in postmenopausal patients
A majority of the Panel considered that an aromatase inhibitor
should form part of standard endocrine therapy for
postmenopausal women with receptor-positive breast cancer,
though acknowledging that there were certain patients for
whom tamoxifen alone can be considered adequate. There was
division about the proper duration of treatment with aromatase
inhibitors, though it was pointed out that safety data beyond 5
years are not yet available. The majority of the Panel preferred
aromatase inhibitors as up-front endocrine treatment
particularly in patients at higher risk of early relapse.
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Updated results from two of the trastuzumab trials were
presented continuing to demonstrate the value of this therapy for
patients with HER2-positive disease. The FinHER trial evaluated
a short course of trastuzumab, which is currently being
compared with a conventional 1-year duration. Meanwhile, the
standard duration of trastuzumab therapy remains 1 year. The
Panel noted that no results are yet available from the 2-year
trastuzumab group in the HERA trial. Interestingly, a majority of
the Panel was prepared, for selected women, to contemplate
trastuzumab with endocrine therapy but without chemotherapy
despite the absence of clinical trial evidence to support this
approach. Finally, the limited evidence of increased risk among
patients with HER2-positive tumours <1 cm in size without
axillary nodal involvement does not allow deﬁnitive
recommendation regarding anti-HER2 therapy in this group.
adjuvant chemotherapy
Two situations were recognised in which the decision to use
adjuvant chemotherapy was relatively clear-cut. First, adjuvant
systemic therapy for patients with triple-negative disease is
essentially limited to chemotherapy, and most such patients are
at sufﬁcient risk to justify this treatment. Secondly, as noted
above, chemotherapy is conventionally given with or preceding
trastuzumab for patients with HER2-positive invasive breast
cancer. The remaining patients—those with ER-positive,
HER2-negative disease—are the group in whom decisions
about adjuvant chemotherapy are most difﬁcult (Table 3). The
Panel recognised that patients whose tumours contained high
levels of ER derived less beneﬁt from addition of chemotherapy
to endocrine therapy. There was no agreement about the
deﬁnition of a standard chemotherapy regimen for any disease
subset. Taxane-containing regimens were discussed and
combinations containing docetaxel and cyclophosphamide as
well as dose-dense doxorubicin and cyclophosphamide
followed by paclitaxel were viewed as standard therapies among
several other regimens.
neoadjuvant systemic therapy
Neoadjuvant systemic therapy was considered justiﬁed
primarily to enhance the possibility of breast-conserving
surgery. If indicated, the majority of the Panel considered that
the neoadjuvant chemotherapy regimen should include both
a taxane and an anthracycline and (for HER2-positive disease)
an anti-HER2 drug. Thus, the choice of a regimen for adjuvant
or neoadjuvant chemotherapy might be made using similar
criteria. Neoadjuvant endocrine therapy without chemotherapy
was considered reasonable for postmenopausal patients with
strongly receptor-positive disease. If used, such treatment
should be considered for a duration of 5–8 months or until
maximum tumour response.
preservation of fertility
Pregnancy after diagnosis of breast cancer has not been shown
to negatively impact prognosis. Women should be counselled
about options for preserving fertility. The Panel did not
consider that any currently available methods for preservation
of fertility following chemotherapy were of proven value,
though gonadotropin-releasing hormone agonists are used
occasionally. These are being tested in an ongoing clinical trial
for women with endocrine nonresponsive disease who are
receiving alkylating agents. Cryoconservation and
retransplantation of ovarian tissue are also experimental.
use of bisphosphonates
Emerging information on bone protection from
demineralisation and tumour by bisphosphonates was viewed
as interesting, but the Panel did not consider that routine use of
bisphosphonates was indicated for women with normal bone
health receiving adjuvant endocrine therapy.
male breast cancer
The Panel considered that adjuvant tamoxifen was standard
therapy and did not endorse the use of adjuvant aromatase
inhibitors in men with breast cancer.
commentary
The present report proposes a new approach to the separate
selection of each treatment modality according to its most
relevant indications. We look forward to future studies more
accurately deﬁning the value of various high-throughput
technologies in assessing the level of risk and likelihood of
response to speciﬁc therapies. Meanwhile, careful application of
the presently available therapies described in this report offers
great value to women with early breast cancer.
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